Co-Authors
This is a "connection" page, showing publications co-authored by MICHELLE DIANNE WILLIAMS and MARIE-CLAUDE HOFMANN.
Connection Strength
0.552
-
RAC1 Alterations Induce Acquired Dabrafenib Resistance in Association with Anaplastic Transformation in a Papillary Thyroid Cancer Patient. Cancers (Basel). 2021 Sep 30; 13(19).
Score: 0.208
-
Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAFV600E Mutant Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Study. Thyroid. 2023 04; 33(4):484-491.
Score: 0.058
-
Novel Anaplastic Thyroid Cancer PDXs and Cell Lines: Expanding Preclinical Models of Genetic Diversity. J Clin Endocrinol Metab. 2021 10 21; 106(11):e4652-e4665.
Score: 0.052
-
A High-throughput Approach to Identify Effective Systemic Agents for the Treatment of Anaplastic Thyroid Carcinoma. J Clin Endocrinol Metab. 2021 09 27; 106(10):2962-2978.
Score: 0.052
-
Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid Carcinoma. Thyroid. 2021 08; 31(8):1235-1243.
Score: 0.050
-
Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019. JAMA Oncol. 2020 09 01; 6(9):1397-1404.
Score: 0.048
-
Circulating BRAF V600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma. JCO Precis Oncol. 2018 Nov; 2:1-11.
Score: 0.042
-
Neoadjuvant BRAF- and Immune-Directed Therapy for Anaplastic Thyroid Carcinoma. Thyroid. 2018 07; 28(7):945-951.
Score: 0.041